-+ 0.00%
-+ 0.00%
-+ 0.00%

Dyadic's C1-Produced RSV, Malaria Antibodies Advance to Animal Studies

PUBT·11/12/2026 12:49:00
Listen to the news
Dyadic's C1-Produced RSV, Malaria Antibodies Advance to Animal Studies
  • Dyadic International's C1-produced RSV and malaria antibodies entered animal studies led by the Gates Medical Research Institute.
  • The studies compare antibody pharmacokinetics against mammalian-cell-produced counterparts across four groups of mice.
  • Testing began October 20, 2026, with results expected in the first quarter of 2027.
  • Seven-day fermentation runs yielded approximately 12.1 g/L for RSV antibody RSM01 and 13.2 g/L for malaria antibody MAM01.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730OMX_____CNEWS_EN_GNW9876260_en) on November 12, 2026, and is solely responsible for the information contained therein.